State of Alaska Department of Revenue Sells 7,302 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

State of Alaska Department of Revenue cut its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 9.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 69,547 shares of the biopharmaceutical company’s stock after selling 7,302 shares during the quarter. State of Alaska Department of Revenue’s holdings in Dynavax Technologies were worth $774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Nordea Investment Management AB grew its holdings in Dynavax Technologies by 23.0% in the 1st quarter. Nordea Investment Management AB now owns 393,781 shares of the biopharmaceutical company’s stock worth $4,924,000 after acquiring an additional 73,681 shares during the last quarter. Mizuho Markets Americas LLC boosted its holdings in shares of Dynavax Technologies by 16.9% during the first quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock worth $10,574,000 after purchasing an additional 123,300 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Dynavax Technologies in the third quarter worth about $8,291,000. Millennium Management LLC purchased a new position in Dynavax Technologies during the 2nd quarter valued at about $17,615,000. Finally, Vanguard Group Inc. raised its position in Dynavax Technologies by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after purchasing an additional 126,458 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DVAX shares. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a report on Tuesday, October 15th.

Dynavax Technologies Price Performance

DVAX stock opened at $12.29 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The firm has a 50-day moving average of $11.11 and a 200 day moving average of $11.23. The company has a market cap of $1.61 billion, a P/E ratio of 111.74 and a beta of 1.34.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. The company had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period in the previous year, the company posted $0.03 earnings per share. On average, sell-side analysts forecast that Dynavax Technologies Co. will post 0.16 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.